---
title: 5-MeO-DMT
description: 
published: true
date: 2026-01-30T09:23:18.389Z
tags: 
editor: markdown
dateCreated: 2026-01-30T05:54:27.833Z
---

[â—€è¿”å›](/è¯ç‰©/home.md)

# 5-MeO-DMT

<mark> æ”¹äº†promptï¼Œæœç„¶å¾ˆæŠ½è±¡ï¼Œä¸‹æ¬¡ä¸å¹²äº†</mark>

[![](/æ–‡ä»¶/Dialog-warning.svg.png)](/æ–‡ä»¶/Dialog-warning.svg.png) **è­¦å‘Šï¼š5-MeO-DMT *ä¸æ˜¯* DMT çš„æœ‰æ•ˆæ›¿ä»£å“å–µã€‚** å°½ç®¡å®ƒä»¬çš„åå­—çœ‹èµ·æ¥å¾ˆåƒï¼Œä½† 5-MeO-DMT å’Œ [DMT](./DMT.md "DMT") æœ‰ç€æˆªç„¶ä¸åŒçš„æ•ˆåº”å’Œé£é™©æ¦‚å†µï¼Œåº”å½“è¢«è§†ä¸ºå®Œå…¨ç‹¬ç«‹çš„ä¸¤ç§ä¸œè¥¿å–µã€‚è¯·æŸ¥çœ‹[è¿™ä¸€éƒ¨åˆ†](#æ¯’æ€§å’Œå±å®³æ€§ "5-MeO-DMT")ä»¥è·å–æ›´å¤šä¿¡æ¯ã€‚

| **5-MeO-DMT ä¿¡æ¯æ‘˜è¦** |
| --- |
| [![5-MeO-DMT.svg](/æ–‡ä»¶/5-MeO-DMT.svg)](/æ–‡ä»¶/5-MeO-DMT.svg) |
| **åŒ–å­¦å‘½å** |
| é€šç”¨åç§° | *5-MeO-DMT, ä¸Šå¸åˆ†å­ (The God Molecule), èŸ¾èœ (Toad), ç¾æ´²è™ (Jaguar)* |
| å–ä»£åç§° | *5-Methoxy-N,N-dimethyltryptamine* |
| ç³»ç»Ÿå‘½å | *2-(5-Methoxy-1H-indol-3-yl)-N,N-dimethylethanamine* |
| **åˆ†ç±»æˆå‘˜** |
| ç²¾ç¥æ´»æ€§åˆ†ç±» | *[è¿·å¹»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Psychedelic")* |
| åŒ–å­¦åˆ†ç±» | *[è‰²èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‰²èƒºç±»ç‰©è´¨.md "Tryptamine")* |
| **[ç»™è¯é€”å¾„](/æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of Administration")** |

**è­¦å‘Šï¼š** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€æ–°é™ˆä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»ä½å‰‚é‡å¼€å§‹å–µã€‚[å‚è§è´Ÿè´£ä»»çš„ç”¨è¯éƒ¨åˆ†](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")ã€‚

| â‡£ [æŠ½å¸](/æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of Administration") | |
| --- | --- |
| **[ç»™è¯å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage")** | |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 1 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 3 - 6 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 6 - 12 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 12 - 20 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 20 mg + |
| **[è¯æ•ˆæ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration")** | |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 20 - 40 åˆ†é’Ÿ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 5 - 60 ç§’ |
| [è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 30 - 60 ç§’ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 5 - 15 åˆ†é’Ÿ |
| [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 10 - 20 åˆ†é’Ÿ |
| [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 15 - 60 åˆ†é’Ÿ |

| â‡£ [é¼»å¸](/æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of Administration") | |
| --- | --- |
| **[ç»™è¯å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage")** | |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 3 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 5 - 8 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 8 - 15 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 15 - 25 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md "Dosage classification") | 25 mg + |
| **[è¯æ•ˆæ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration")** | |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 2 - 3 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 1 - 10 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 10 - 40 åˆ†é’Ÿ |
| [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 30 - 60 åˆ†é’Ÿ |
| [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md "Duration") | 1 - 3 å°æ—¶ |

- **[å…è´£å£°æ˜](/æ–‡æ¡£/å…³äºæœ¬ç«™/è§‚å‰æé†’.md "Disclaimer"):** æœ¬ç«™çš„[ç»™è¯å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md "Dosage")ä¿¡æ¯ä»…ä¾›æ•™è‚²ç›®çš„ï¼Œæ”¶é›†è‡ªç”¨æˆ·å’Œèµ„æºã€‚å®ƒä¸æ˜¯æ¨èï¼Œåº”ä¸å…¶ä»–æ¥æºæ ¸å®ä»¥ç¡®ä¿å‡†ç¡®æ€§å–µã€‚

| **[ç›¸äº’ä½œç”¨](#å±é™©çš„ç›¸äº’ä½œç”¨)** | |
| --- | --- |
| [2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨.md) (2C-X) | ğŸ’” è”ç”¨å±é™© |
| [å¤§éº»](./å¤§éº».md) | âš ï¸ è°¨æ…è”ç”¨ |
| DOx | ğŸ’” è”ç”¨å±é™© |
| [MDMA](./MDMA.md) | âš ï¸ è°¨æ…è”ç”¨ |
| [éº¦æ–¯å¡æ—](./éº¦æ–¯å¡æ—.md) | âš ï¸ è°¨æ…è”ç”¨ |
| NBOMe | ğŸ’” è”ç”¨å±é™© |
| [è‹¯ä¸™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md) | âš ï¸ è°¨æ…è”ç”¨ |
| [å¯å¡å› ](./å¯å¡å› .md) | âš ï¸ è°¨æ…è”ç”¨ |
| [å³ç¾æ²™èŠ¬](./å³ç¾æ²™èŠ¬.md) (DXM) | â“ æœªçŸ¥/æ…ç”¨ |
| [æ›²é©¬å¤š](./æ›²é©¬å¤š.md) | â›” ä¸¥ç¦è”ç”¨ |
| aMT | â›” ä¸¥ç¦è”ç”¨ |
| [å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚.md) (MAOIs) | â›” ä¸¥ç¦è”ç”¨ |
| [PCP](./PCP.md) | â“ æœªçŸ¥/æ…ç”¨ |

**5-ç”²æ°§åŸº-N,N-äºŒç”²åŸºè‰²èƒº**ï¼ˆä¹Ÿè¢«ç§°ä¸º **5-MeO-DMT**ï¼‰æ˜¯ä¸€ç§[è‰²èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‰²èƒºç±»ç‰©è´¨.md "Tryptamine")ç±»åˆ«çš„[å¤©ç„¶å­˜åœ¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/home.md "Naturally-occurring")çš„[è¿·å¹»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Psychedelic")ã€‚å®ƒåœ¨ç»“æ„ä¸Šä¸ [DMT](./DMT.md "DMT") å’Œ 5-HO-DMT (*bufotenin*) ç›¸å…³ï¼Œå¹¶è¢«è®¤ä¸ºåœ¨è¯¥ç±»åˆ«ä¸­èƒ½äº§ç”Ÿæœ€å¼ºå¤§å’Œæœ€å¼ºçƒˆçš„è¿·å¹»çŠ¶æ€å–µã€‚5-MeO-DMT é€šè¿‡ç»“åˆå¤§è„‘ä¸­çš„[è¡€æ¸…ç´ ](/æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")[å—ä½“](/æ–‡æ¡£/å—ä½“æ¿€åŠ¨å‰‚.md "Receptors")äº§ç”Ÿæ•ˆåº”ï¼Œå°½ç®¡å…¶ç¡®åˆ‡æœºåˆ¶å°šä¸æ¸…æ¥šã€‚

å®ƒåˆ†å¸ƒåœ¨å¤šç§æ¤ç‰©ç‰©ç§ä»¥åŠä¸€ç§å•ä¸€çš„èŸ¾èœç‰©ç§ï¼ˆ*Incilius alvarius*ï¼Œç§‘ç½—æ‹‰å¤šæ²³èŸ¾èœï¼‰çš„æ¯’æ¶²ä¸­ã€‚å°½ç®¡å¯¹å…¶å†å²çŸ¥ä¹‹ç”šå°‘ï¼Œä½†æ®ä¿¡å®ƒå‡ ä¸ªä¸–çºªä»¥æ¥ä¸€ç›´è¢«ç”¨äºå—ç¾è¨æ»¡æ•™çš„å®è·µä¸­ã€‚åœ¨ç°ä»£ï¼ŒèŸ¾èœæ¯’æ¶²çš„æå–ç‰©ä»¥åŠåˆæˆç²‰æœ«å½¢å¼éƒ½åœ¨ä½¿ç”¨ï¼Œä¸»è¦é€šè¿‡[æ±½åŒ–](/æ–‡æ¡£/ç»™è¯é€”å¾„.md "Vaporization")ï¼ˆå¸å…¥è’¸æ±½ï¼‰çš„æ–¹å¼æ‘„å…¥å–µã€‚

äºšå†å±±å¤§Â·èˆ’å°”é‡‘ï¼ˆAlexander Shulginï¼‰åœ¨ä»– 1997 å¹´çš„ä¹¦ã€ŠTiHKALã€‹ï¼ˆâ€œæˆ‘æ‰€ç†ŸçŸ¥å’Œå–œçˆ±çš„è‰²èƒºâ€ï¼‰ä¸­è®°å½•äº†å…¶åˆæˆå’Œç²¾ç¥æ´»æ€§æ•ˆåº”ã€‚æœ€è¿‘çš„ç ”ç©¶è¯æ˜äº†å…¶è¯±å¯¼ç¥ç§˜ä½“éªŒçš„èƒ½åŠ›[\[1\]](#cite_note-1)ï¼Œå¹¶ä¸”äººä»¬å¯¹å…¶æ½œåœ¨æ²»ç–—æ•ˆæœçš„æ¢ç´¢è¶Šæ¥è¶Šæ„Ÿå…´è¶£ã€‚

[ä¸»è§‚æ•ˆåº”](/æ–‡æ¡£/å…³äºæœ¬ç«™/è§‚å‰æé†’.md "Subjective effects")åŒ…æ‹¬[è”åˆä¸äº’è”](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Unity and interconnectedness")ã€[æ—¶é—´æ‰­æ›²](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Time distortion")ã€[æ¦‚å¿µæ€§æ€ç»´](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Conceptual thinking")ã€[æ¬£å¿«æ„Ÿ](/è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md "Euphoria")å’Œ[è‡ªæˆ‘æ¶ˆäº¡](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Ego loss")ã€‚5-MeO-DMT çš„è¿·å¹»æ•ˆåº”åœ¨å¼ºåº¦ï¼ˆæé«˜ï¼‰å’ŒæŒç»­æ—¶é—´ï¼ˆæçŸ­ï¼‰æ–¹é¢æœ€å¥½ä¸ [DMT](./DMT.md "DMT") è¿›è¡Œæ¯”è¾ƒã€‚ç„¶è€Œï¼Œå®ƒé€šå¸¸ç¼ºä¹[è§†è§‰å‡ ä½•](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Geometry")æˆåˆ†ï¼Œå¹¶ä¸”å€¾å‘äºäº§ç”Ÿæ›´å¤šçš„[èº¯ä½“æ¬£å¿«æ„Ÿ](/è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md "Physical euphoria")ä»¥åŠæ¯” DMT æ›´å¼ºçš„[è¶…ä¸ªäºº](/æ–‡æ¡£/ç²¾ç¥æ¢ç´¢.md "Transpersonal")æˆ–ç±»ç¥ç§˜æ•ˆåº”ï¼ˆä¾‹å¦‚[è‡ªæˆ‘æ¶ˆäº¡](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Ego loss")ï¼‰å–µã€‚

æ­¤å¤–ï¼Œæ®æŠ¥é“ï¼Œç²¾ç¥å’Œèº«ä½“ä¸Šçš„å‰¯ä½œç”¨åœ¨ 5-MeO-DMT ä¸­æ›´å¸¸å‘ç”Ÿã€‚è¿™äº›æ•ˆåº”åŒ…æ‹¬æ˜æ˜¾çš„[ç„¦è™‘](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Anxiety")å’Œ[çƒ¦èº](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Cognitive dysphoria")ï¼Œä»¥åŠ[æ¶å¿ƒ](/è¯æ•ˆ/æ¶å¿ƒ.md "Nausea")å’Œ[èº¯ä½“ä¸é€‚æ„Ÿ](/è¯æ•ˆ/ä¸é€‚æ€§èº¯ä½“æ•ˆåº”.md "Body load")ï¼Œå¹¶ä¸”é€šå¸¸è¢«æè¿°ä¸ºå…·æœ‰æŒ‘æˆ˜æ€§å’Œå‹å€’æ€§çš„ã€‚

ä¸ [DMT](./DMT.md "DMT")ï¼ˆå·²è¢«è¯æ˜å…·æœ‰æå°çš„ç”Ÿç†æ¯’æ€§ï¼‰ä¸åŒï¼Œ5-MeO-DMT çš„å®‰å…¨æ€§æ¦‚å†µå°šæœªç¡®å®šã€‚å°‘æ•°æ­»äº¡æ¡ˆä¾‹ä¸å…¶ä½¿ç”¨æœ‰å…³ï¼Œä¼¼ä¹æ˜¯èº«ä½“è¿‡é‡æœç”¨çš„ç»“æœã€‚ä¸€äº›æŠ¥å‘Šè¡¨æ˜ï¼Œå½“ä¸æŸäº›ç‰©è´¨ï¼ˆå¦‚[å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚.md "MAOIs")ï¼‰ç»“åˆä½¿ç”¨æ—¶ï¼Œå®ƒå¯èƒ½ä¼šå¯¼è‡´è¡€æ¸…ç´ æ¯’æ€§ï¼›å®ƒä¹Ÿå¯èƒ½å…·æœ‰å¿ƒè„æ¯’æ€§ç‰¹æ€§å–µã€‚

è½¶äº‹æŠ¥å‘Šè¡¨æ˜ï¼Œè¿™ç§ç‰©è´¨ä»…é€‚ç”¨äºå…·æœ‰ä¸°å¯Œå¼ºæ•ˆè¿·å¹»å‰‚ç»éªŒï¼ˆä¾‹å¦‚ [DMT](./DMT.md "DMT")ã€[æ­»è—¤æ°´](./æ­»è—¤æ°´.md "Ayahuasca")å’Œ [DPT](./DPT.md "DPT")ï¼‰å¹¶æ¥å—è¿‡å®‰å…¨ä½¿ç”¨åŸ¹è®­çš„ç”¨æˆ·ã€‚å¦‚æœä½¿ç”¨æ­¤ç‰©è´¨ï¼Œå¼ºçƒˆå»ºè®®é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Harm reduction practices")å–µã€‚

ç›®å½•
--------

* [1 åŒ–å­¦](#åŒ–å­¦)
    + [1.1 å†…æºæ€§å­˜åœ¨](#å†…æºæ€§å­˜åœ¨)
* [2 è¯ç†å­¦](#è¯ç†å­¦)
* [3 ä¸»è§‚æ•ˆåº”](#ä¸»è§‚æ•ˆåº”)
    + [3.1 **èº¯ä½“æ•ˆåº”**](#èº¯ä½“æ•ˆåº”)
    + [3.2 **è§†è§‰æ•ˆåº”**](#è§†è§‰æ•ˆåº”)
        - [3.2.1 å‡ ä½•](#å‡ ä½•)
    + [3.3 **è®¤çŸ¥æ•ˆåº”**](#è®¤çŸ¥æ•ˆåº”)
    + [3.4 **å¬è§‰æ•ˆåº”**](#å¬è§‰æ•ˆåº”)
    + [3.5 **è¶…ä¸ªäººæ•ˆåº”**](#è¶…ä¸ªäººæ•ˆåº”)
    + [3.6 ä½“éªŒæŠ¥å‘Š](#ä½“éªŒæŠ¥å‘Š)
* [4 ç»™è¯é€”å¾„](#ç»™è¯é€”å¾„)
    + [4.1 æ±½åŒ–](#æ±½åŒ–)
    + [4.2 å£æœ](#å£æœ)
* [5 å¤©ç„¶æ¥æº](#å¤©ç„¶æ¥æº)
    + [5.1 ç§‘ç½—æ‹‰å¤šæ²³èŸ¾èœ](#ç§‘ç½—æ‹‰å¤šæ²³èŸ¾èœ)
        - [5.1.1 å‰‚é‡](#å‰‚é‡)
* [6 æ¯’æ€§å’Œå±å®³æ€§](#æ¯’æ€§å’Œå±å®³æ€§)
    + [6.1 ä¾èµ–æ€§å’Œæ»¥ç”¨æ½œåŠ›](#ä¾èµ–æ€§å’Œæ»¥ç”¨æ½œåŠ›)
    + [6.2 å±é™©çš„ç›¸äº’ä½œç”¨](#å±é™©çš„ç›¸äº’ä½œç”¨)
* [7 æ³•å¾‹åœ°ä½](#æ³•å¾‹åœ°ä½)
* [8 å¦è§](#å¦è§)
* [9 å¤–éƒ¨é“¾æ¥](#å¤–éƒ¨é“¾æ¥)
    + [9.1 è®¨è®º](#è®¨è®º)
* [10 æ–‡çŒ®](#æ–‡çŒ®)
    + [10.1 ä¹¦ç±](#ä¹¦ç±)
* [11 å‚è€ƒèµ„æ–™](#å‚è€ƒèµ„æ–™)

åŒ–å­¦
---------

[![](/æ–‡ä»¶/Substituted_tryptamine.svg)](/æ–‡ä»¶/Substituted_tryptamine.svg)

è‰²èƒºåˆ†å­çš„é€šç”¨ç»“æ„ã€‚

5-MeO-DMT æˆ– 5-ç”²æ°§åŸº-N,N-äºŒç”²åŸºè‰²èƒºæ˜¯ä¸€ç§[è‰²èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‰²èƒºç±»ç‰©è´¨.md "Tryptamine")ç±»åˆ«çš„ç¯å–ä»£å²å“šç”Ÿç‰©ç¢±åˆ†å­ã€‚è‰²èƒºå…±äº«ä¸€ä¸ªæ ¸å¿ƒç»“æ„ï¼Œè¯¥ç»“æ„ç”±ä¸€ä¸ªåŒç¯å²å“šæ‚ç¯ç»„æˆï¼Œè¯¥æ‚ç¯é€šè¿‡ä¹™åŸºä¾§é“¾åœ¨ R3 å¤„è¿æ¥åˆ°ä¸€ä¸ªæœ«ç«¯èƒºåŸºã€‚5-MeO-DMT åœ¨å…¶å²å“šæ‚ç¯çš„ R5 å¤„è¢«ç”²æ°§åŸº (MeO) å®˜èƒ½å›¢ CH3Oâˆ’ å–ä»£ï¼›å®ƒè¿˜åœ¨å…¶è‰²èƒºéª¨æ¶ (DMT) çš„æœ«ç«¯èƒº RN ä¸Šå«æœ‰ä¸¤ä¸ªç”²åŸº CH3-ã€‚

5-MeO-DMT æ˜¯ [5-MeO-MiPT](./5-MeO-MiPT.md "5-MeO-MiPT") å’Œ [5-MeO-DiPT](./5-MeO-DiPT.md "5-MeO-DiPT") çš„ N-å–ä»£ç”²åŸºåŒç³»ç‰©ï¼Œå°½ç®¡å®ƒçš„æ•ˆåº”æˆªç„¶ä¸åŒå–µã€‚[\[2\]](#cite_note-TiHKAL-2)

### å†…æºæ€§å­˜åœ¨

5-MeO-DMT ä¹Ÿè¢«è¯æ˜åœ¨äººä½“å†…ä¼šäº§ç”Ÿå¾®é‡çš„å†…æºæ€§ç”Ÿæˆï¼Œå°½ç®¡å…¶ç”Ÿç‰©å­¦åŠŸèƒ½ï¼ˆå¦‚æœæœ‰çš„è¯ï¼‰å°šä¸æ¸…æ¥šã€‚[\[3\]](#cite_note-Shen2010-3)

è¯ç†å­¦
------------

æ›´å¤šä¿¡æ¯ï¼š[è¡€æ¸…ç´ èƒ½è¿·å¹»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Serotonergic psychedelic")

5-MeO-DMT çš„[è¿·å¹»](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Psychedelic")æ•ˆåº”ä¸»è¦è¢«è®¤ä¸ºæ¥è‡ªå…¶ä½œä¸º[éƒ¨åˆ†æ¿€åŠ¨å‰‚](/æ–‡æ¡£/å—ä½“æ¿€åŠ¨å‰‚.md "Partial agonist")åœ¨ [5-HT1A å—ä½“](/æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")ä¸Šçš„åŠŸæ•ˆã€‚å…·ä½“è€Œè¨€ï¼Œè¯¥åˆ†å­æ˜¾ç¤ºå‡ºå¯¹ 5-HT1A äºšå‹çš„é«˜ç»“åˆäº²å’ŒåŠ›ï¼Œè€Œå¯¹ 5-HT2a äºšå‹çš„ç»“åˆåŠ›ç›¸å¯¹è¾ƒä½ã€‚[\[4\]](#cite_note-Krebs-ThomsonRuiz2006-4) ç”±äºå¸¸è§çš„è¿·å¹»å‰‚è¢«è®¤ä¸ºä¸»è¦é€šè¿‡ 5-HT2a å—ä½“æ´»æ€§å¼•å‘å…¶æ•ˆåº”ï¼Œå› æ­¤è¯¥è¯ç‰©çš„ç»“åˆæ¦‚å†µä»¥åŠå®ƒæ˜¯å¦‚ä½•å¯¼è‡´[è¿·å¹»](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Psychedelic")ä½“éªŒçš„ä»ç„¶éš¾ä»¥æ‰æ‘¸å–µã€‚

å…¶ä»–ä½œç”¨æœºåˆ¶ï¼Œå¦‚[è¡€æ¸…ç´ ](/æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")ã€[å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md "Noradrenaline")å’Œ[å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine")ç­‰[ç¥ç»é€’è´¨](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Neurotransmitters")çš„[é‡æ‘„å–æŠ‘åˆ¶](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Reuptake inhibition")ï¼Œä¹Ÿè¢«è®¤ä¸ºåœ¨ä¸€å®šç¨‹åº¦ä¸Šå‚ä¸å…¶ä¸­ã€‚[\[5\]](#cite_note-pmid17223101-5) è¿™å¯èƒ½å¯¼è‡´ 5-MeO-DMT åœ¨ä¸[å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚.md "MAOIs")ã€[å¯é€†æ€§å•èƒºæ°§åŒ–é…¶AæŠ‘åˆ¶å‰‚](/æ–‡æ¡£/å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚.md "RIMA") (RIMAs)ã€[é€‰æ‹©æ€§è¡€æ¸…ç´ å†æ‘„å–æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "SSRI") (SSRIs)ã€[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulant")æˆ–ä»»ä½•ä½œä¸º[å•èƒºç¥ç»é€’è´¨](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Monoamine neurotransmitter")çš„[é‡Šæ”¾å‰‚](/æ–‡æ¡£/ç¥ç»é€’è´¨é‡Šæ”¾å‰‚.md "Releasing agent")æˆ–[é‡æ‘„å–æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor")çš„ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶å˜å¾—å…·æœ‰å±é™©çš„æ¯’æ€§ã€‚

5-MeO-DMT è¢«å¤šæ€æ€§ç»†èƒè‰²ç´  P450 2D6 (CYP2D6) è¿›è¡Œ *O*-å»ç”²åŸºåŒ–ï¼Œè½¬åŒ–ä¸ºæ´»æ€§ä»£è°¢ç‰© bufotenin (5-HO-DMT)ã€‚[\[3\]](#cite_note-Shen2010-3)

ä¸»è§‚æ•ˆåº”
------------------

| ![Metacogghjgjvghnition.png](/æ–‡ä»¶/Metacogghjgjvghnition.png) | **ä¸»è§‚æ•ˆåº”éƒ¨åˆ†è¿˜åœ¨æ–½å·¥ä¸­å–µ**ã€‚<br>*å› æ­¤ï¼Œå®ƒä»åœ¨è¿›è¡Œä¸­ï¼Œå¯èƒ½åŒ…å«ä¸å®Œæ•´æˆ–é”™è¯¯çš„ä¿¡æ¯ã€‚*<br>*ä½ å¯ä»¥å¸®å¿™[æ‰©å±•æˆ–çº æ­£å®ƒã€‚](https://psychonautwiki.org/w/index.php?title=5-MeO-DMT&action=edit)* |
| --- | --- |

ä¸å…¶é€šå¸¸ç›¸å¯¹æ¸©å’Œçš„ä¼´éšè®¤çŸ¥å’Œè§†è§‰æ•ˆåº”ç›¸æ¯”ï¼Œ5-MeO-DMT ä¼¼ä¹å…·æœ‰è¿„ä»Šä¸ºæ­¢åœ¨å·²çŸ¥è¿·å¹»ä½“éªŒä¸­å‘ç°çš„æœ€æˆæ¯”ä¾‹çš„å¼ºçƒˆå’Œå‹å€’æ€§çš„èº¯ä½“æ„Ÿè§‰ã€‚è¿™äº›å•ç‹¬çš„ç»„æˆéƒ¨åˆ†æ˜¯å¤æ‚çš„ã€å‹å€’æ€§çš„ï¼Œå¹¶ä¸”ä¼¼ä¹åŒæ ·èƒ½å¤Ÿè¢«è§£é‡Šä¸ºæåº¦æ„‰æ‚¦å’Œæ¬£å¿«ï¼Œæˆ–è€…æ˜¯æåº¦ä¸èˆ’æœå’Œçƒ¦èºã€‚

***å…è´£å£°æ˜ï¼š** ä¸‹åˆ—æ•ˆåº”å¼•ç”¨è‡ª [***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](/æ–‡æ¡£/å…³äºæœ¬ç«™/è§‚å‰æé†’.md "Subjective effect index") (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ [PsychonautWiki](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md "PsychonautWiki") è´¡çŒ®è€…ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”å¸¦ç€å¥åº·çš„æ€€ç–‘æ€åº¦æ¥çœ‹å¾…å®ƒä»¬å–µã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡è¾ƒé«˜çš„å‰‚é‡æ›´å¯èƒ½è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚* åŒæ ·ï¼Œ**ä¸è‰¯ååº”**åœ¨è¾ƒé«˜å‰‚é‡ä¸‹å˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¹¶ä¸”å¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡** â˜ ã€‚

### **èº¯ä½“æ•ˆåº”**

*     + **[è‡ªå‘çš„èº¯ä½“æ„Ÿè§‰](/è¯æ•ˆ/èº¯ä½“æ•ˆåº”.md "Spontaneous bodily sensations")** - è¿™ä¹Ÿè®¸æ˜¯ 5-MeO-DMT ä½“éªŒä¸­æœ€æ˜¾è‘—çš„æ„Ÿè§‰ã€‚å®ƒå°†èº«ä½“å’Œè§¦è§‰æ„Ÿè§‰çš„å¼ºåº¦æé«˜åˆ°å¦‚æ­¤å‹å€’æ€§çš„ç¨‹åº¦ï¼Œä»¥è‡³äºå®ƒå¯ä»¥åœ¨å…¨èº«çš„æ¯ä¸€ä¸ªç¥ç»æœ«æ¢¢å¼•èµ·æŒç»­å’Œå¯é‡å¤çš„å…¨èº«é«˜æ½®çš„æ„Ÿè§‰ï¼Œå…¶ç¨‹åº¦åœ¨ä»»ä½•å…¶ä»–è¿·å¹»ç‰©è´¨ä¸­éƒ½æ‰¾ä¸åˆ°ã€‚è¿™ç§ä½“éªŒå¯èƒ½ä¼šå¯¼è‡´ä¸€ç§æ„Ÿè§‰ï¼Œå³éš¾ä»¥ç»´æŒå‘¼å¸åŠ¨ä½œã€‚ç„¶è€Œï¼Œè¿™å¹¶ä¸æ˜¯çœŸæ­£çš„æˆ–å±é™©çš„[å‘¼å¸æŠ‘åˆ¶](/è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md "Respiratory depression")ä½“éªŒï¼Œå¹¶è¢«è®¤ä¸ºæ˜¯å®‰å…¨çš„ï¼Œå°½ç®¡ç¼ºä¹å¯¹è¿™ç§ç°è±¡çš„ç ”ç©¶å–µã€‚
    + **[èº¯ä½“æ¬£å¿«æ„Ÿ](/è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md "Physical euphoria")**
    + **[è§¦è§‰å¢å¼º](/è¯æ•ˆ/è§¦è§‰æ•ˆåº”.md "Tactile enhancement")**
    + **[èº¯ä½“æ²‰é‡æ„Ÿ](/è¯æ•ˆ/èº¯ä½“æ²‰é‡æ„Ÿ.md "Perception of bodily heaviness")**
    + **[èº¯ä½“æ§åˆ¶å¢å¼º](/è¯æ•ˆ/èº¯ä½“æ§åˆ¶å¢å¼º.md "Bodily control enhancement")**
    + **[èº¯ä½“å‹åŠ›æ„Ÿ](/è¯æ•ˆ/èº¯ä½“å‹åŠ›æ„Ÿ.md "Bodily pressures")**
    + **[èº¯ä½“å½¢æ€æ„Ÿæ”¹å˜](/è¯æ•ˆ/èº¯ä½“å½¢æ€æ„Ÿæ”¹å˜.md "Changes in felt bodily form")**
    + **[é‡åŠ›æ„Ÿæ”¹å˜](/è¯æ•ˆ/é‡åŠ›æ„Ÿæ”¹å˜.md "Changes in felt gravity")**
    + **[èº¯ä½“è‡ªä¸»](/è¯æ•ˆ/èº¯ä½“è‡ªä¸».md "Physical autonomy")**
    + **[è‚Œè‚‰æ”¶ç¼©](/è¯æ•ˆ/è‚Œè‚‰ç´§å¼ .md "Muscle contractions")**
    + **[è‚Œè‚‰ç—‰æŒ›](/è¯æ•ˆ/è‚Œè‚‰ç—‰æŒ›.md "Muscle spasms")**
    + **[è‚Œè‚‰é¢¤åŠ¨](/è¯æ•ˆ/è‚Œè‚‰é¢¤åŠ¨.md "Muscle tremors")**
    + **[è¿åŠ¨æ§åˆ¶ä¸§å¤±](/è¯æ•ˆ/è¿åŠ¨æ§åˆ¶ä¸§å¤±.md "Motor control loss")**
    + **[å‘¼å¸æŠ‘åˆ¶](/è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md "Respiratory depression")**
    + **[æ¶å¿ƒ](/è¯æ•ˆ/æ¶å¿ƒ.md "Nausea")** - 5-MeO-DMT å¼•èµ·çš„æ¶å¿ƒå¯èƒ½æ¯”ä»»ä½•å…¶ä»–è¿·å¹»å‰‚éƒ½æ›´æ˜æ˜¾å’ŒæŒç»­ã€‚ç”¨æˆ·åœ¨æ— æ„è¯†æˆ–åŠæ„è¯†çŠ¶æ€ä¸‹å‘•åçš„æƒ…å†µå¹¶ä¸å°‘è§ï¼Œè¿™ä¹Ÿæ˜¯å§‹ç»ˆå»ºè®®åœ¨æœ‰äººç›‘ç£ä¸‹ä½¿ç”¨çš„åŸå› ä¹‹ä¸€ã€‚ç„¶è€Œï¼Œæœ‰äº›äººæŠ¥å‘Šè¯´ä½“éªŒåªæœ‰æå°‘æˆ–çŸ­æš‚çš„æ¶å¿ƒã€‚å½“æ¶å¿ƒç¡®å®å‘ç”Ÿæ—¶ï¼Œå®ƒé€šå¸¸åœ¨è¯æ•ˆä¸Šå‡æœŸåæ¶ˆå¤±å–µã€‚
    + **[ç³å­”æ‰©å¤§](/è¯æ•ˆ/ç³å­”æ‰©å¤§.md "Pupil dilation")**
    + **[çš®è‚¤æ½®çº¢](/è¯æ•ˆ/çš®è‚¤æ½®çº¢.md "Skin flushing")**
    + **[ç©ºé—´å®šå‘éšœç¢](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Spatial disorientation")**
    + **[ä½“æ¸©è°ƒèŠ‚æŠ‘åˆ¶](/è¯æ•ˆ/ä½“æ¸©è°ƒèŠ‚æŠ‘åˆ¶.md "Temperature regulation suppression")**

### **è§†è§‰æ•ˆåº”**

* 5-MeO-DMT çš„è§†è§‰æ•ˆåº”å¯ä»¥åˆ†ä¸ºå‡ ä¸ªéƒ¨åˆ†ï¼Œè¿™äº›éƒ¨åˆ†éšç€å‰‚é‡çš„å¢åŠ è€Œé€æ¸å¢å¼ºã€‚ä¸å…¶æŒç»­å‹å€’æ€§å’Œå¼ºçƒˆçš„ä¼´éšè®¤çŸ¥å’Œèº¯ä½“æ•ˆåº”ç›¸æ¯”ï¼Œ5-MeO-DMT ä¼¼ä¹å…·æœ‰å·²çŸ¥è¿·å¹»ä½“éªŒç§ç±»ä¸­æœ€æˆæ¯”ä¾‹çš„å¾®å¼±çš„è§†è§‰æ•ˆåº”ã€‚
    + **[è§†è§‰é”åº¦å¢å¼º](/è¯æ•ˆ/è§†è§‰é”åº¦å¢å¼º.md "Visual acuity enhancement") æˆ– [è§†è§‰é”åº¦æŠ‘åˆ¶](/è¯æ•ˆ/è§†è§‰é”åº¦æŠ‘åˆ¶.md "Visual acuity suppression")** - 5-MeO-DMT åŒæ ·èƒ½å¤Ÿé™ä½å’Œæé«˜è§†è§‰æ•é”åº¦ã€‚å“ªç§æ•ˆåº”ä¼šæ˜¾ç°ä¼¼ä¹å‡ ä¹å®Œå…¨æ˜¯éšæœºé€‰æ‹©çš„ï¼Œå¹¶ä¸”å¾ˆå¤§ç¨‹åº¦ä¸Šå–å†³äºæƒ…å¢ƒã€‚
    + **[æ¼‚ç§»](/è¯æ•ˆ/æ¼‚ç§».md "Drifting")** ([å˜å½¢](/è¯æ•ˆ/æ¼‚ç§».md "Drifting"), [å‘¼å¸](/è¯æ•ˆ/æ¼‚ç§».md "Drifting"), [èåŒ–](/è¯æ•ˆ/æ¼‚ç§».md "Drifting"), [æµåŠ¨](/è¯æ•ˆ/æ¼‚ç§».md "Drifting")) - ä¸å…¶ä»–è¿·å¹»å‰‚ç›¸æ¯”ï¼Œè¿™ç§æ•ˆåº”åœ¨é£æ ¼ä¸Šå¯ä»¥æè¿°ä¸ºä¸ DMT ç›¸åŒï¼Œç»†èŠ‚é«˜åº¦ä¸°å¯Œï¼Œè¿åŠ¨ç¼“æ…¢å¹³æ»‘ï¼Œå¤–è§‚é™æ­¢ã€‚
    + **[é¢œè‰²åç§»](/è¯æ•ˆ/é¢œè‰²åç§».md "Colour shifting")**
    + **[ç¯å¢ƒçƒä½“åŒ–](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Environmental orbism")**
    + **[é€’å½’](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Recursion")**

#### å‡ ä½•
    è´¯ç©¿æ•´ä¸ªæ—…ç¨‹çš„è§†è§‰å‡ ä½•ç»“æ„é€šå¸¸ä¸ä¼šå‘ç”Ÿï¼Œè¿™ä¸ [DMT](./DMT.md "DMT") å½¢æˆé²œæ˜å¯¹æ¯”ï¼Œåœ¨å…¶æœ€é«˜çŠ¶æ€ä¸‹ä¸ä¼šè¶…è¿‡ 7 çº§ï¼ˆå°½ç®¡æœ‰æŠ¥é“ç§°æ¶‰åŠéè§†è§‰çš„ 8b çº§ï¼‰ã€‚å®ƒéšçº¦ç±»ä¼¼äº [DMT](./DMT.md "DMT")ï¼Œä½†å°ºå¯¸æ˜æ˜¾æ›´å°ï¼Œå¹¶ä¸”æ›´æœ‰å¯èƒ½åœ¨é»‘æš—ä¸­æˆ–æ²¡æœ‰å¹²æ‰°çš„æƒ…å†µä¸‹æ˜¾ç°ã€‚å°±å¤–è§‚è€Œè¨€ï¼Œå¯ä»¥é€šè¿‡å…¶[å˜åŒ–](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "Geometry")å…¨é¢æè¿°ä¸ºï¼šå¤æ‚æ€§é”™ç»¼å¤æ‚ï¼Œå½¢å¼æŠ½è±¡ï¼Œæ„Ÿè§‰ä¸Šæœ‰æœºå’Œæ•°å­—å¹¶å­˜ï¼Œç»„ç»‡ç»“æ„åŒ–ï¼Œå…‰çº¿æ˜äº®ï¼Œé…è‰²å¤šå½©ï¼Œé˜´å½±æœ‰å…‰æ³½ï¼Œé”åˆ©å’ŒæŸ”å’Œçš„è¾¹ç¼˜å¹¶å­˜ï¼Œå°ºå¯¸å°ï¼Œé€Ÿåº¦å¿«ï¼Œè¿åŠ¨å¹³æ»‘ï¼Œåœ†è§’å’Œæ£±è§’å¹¶å­˜ï¼Œæ·±åº¦æ²‰æµ¸ä¸”å¼ºåº¦ä¸€è‡´ã€‚5-MeO-DMT çš„ç‹¬ç‰¹ä¹‹å¤„åœ¨äºï¼Œåœ¨çªç ´æ€§å‰‚é‡ä¸‹ï¼Œå®ƒç‹¬ç‰¹åœ°å€¾å‘äºå¯¼è‡´ [8B å‡ ä½•](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "8B Geometry") è€Œä¸æ˜¯ [8A çº§](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md "8A Geometry")ã€‚

### **è®¤çŸ¥æ•ˆåº”**

*     + **[å¤±å¿†](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Amnesia")**
    + **[åˆ†æå¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Analysis enhancement")**
    + **[ç„¦è™‘](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Anxiety")**
    + **[æ¦‚å¿µæ€§æ€ç»´](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Conceptual thinking")**
    + **[æƒ…æ„Ÿå®£æ³„](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Catharsis")**
    + **[å›°æƒ‘](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Confusion")**
    + **[å¦„æƒ³](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Delusion")**
    + **[æƒ…æ„Ÿå¢å¼º](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Emotion enhancement")**
    + **[è®°å¿†æŠ‘åˆ¶](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Memory suppression")**
        - **[è‡ªæˆ‘æ¶ˆäº¡](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Ego death")** - è¿™ç§æ•ˆåº”åœ¨ 5-MeO-DMT ä¸Šæ¯”ä»»ä½•å…¶ä»–å·²çŸ¥ç‰©è´¨éƒ½æ›´ä¸€è‡´å’Œå¯é‡å¤å–µã€‚
    + **[æ­£å¿µ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Mindfulness")**
    + **[å¤å…´æ„Ÿ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Rejuvenation")**
    + **[è‡ªä¸»å£°éŸ³äº¤æµ](/è¯æ•ˆ/å¬è§‰æ•ˆåº”.md "Autonomous voice communication")**
    + **[æ€ç»´è¿é€šæ€§](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Thought connectivity")**
    + **[æ—¶é—´æ‰­æ›²](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Time distortion")**
    + **[æ¸…é†’åº¦](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Wakefulness")**

### **å¬è§‰æ•ˆåº”**

*     + **[å¢å¼º](/è¯æ•ˆ/å¬è§‰æ•ˆåº”.md "Auditory enhancement")**
    + **[æ‰­æ›²](/è¯æ•ˆ/å¬è§‰æ•ˆåº”.md "Auditory distortion")**
    + **[å¹»è§‰](/è¯æ•ˆ/å¬è§‰æ•ˆåº”.md "Auditory hallucinations")**

### **[è¶…ä¸ªäºº](/æ–‡æ¡£/ç²¾ç¥æ¢ç´¢.md "Transpersonal")æ•ˆåº”**

* **æ³¨æ„**ï¼šå¯¹äºè®¸å¤šäººæ¥è¯´ï¼Œè¿™äº›æ•ˆåº”åœ¨æŠ½å¸æˆ–æ±½åŒ– 5-MeO-DMT æ—¶æ¯”å…¶ä»–â€œç»å…¸è¿·å¹»å‰‚â€ï¼ˆå¦‚ [LSD](./LSD.md "LSD") æˆ– [éº¦æ–¯å¡æ—](./éº¦æ–¯å¡æ—.md "Mescaline")ï¼‰æ›´å…·å¯é‡å¤æ€§å’ŒåŠ›é‡ï¼Œè¿™å¾ˆå¯èƒ½æ˜¯ç”±äºå…¶éå¸¸å¼ºçƒˆä½†ç›¸å¯¹çŸ­æš‚çš„æ•ˆåº”ã€‚è¿™äº›æˆåˆ†æ˜¯ 5-MeO-DMT ç‹¬æœ‰çš„ï¼Œå› ä¸ºå¯¹äºå¤§å¤šæ•°ç”¨æˆ·æ¥è¯´ï¼Œå®ƒä»¬æ›´æœ‰å¯èƒ½åœ¨â€œçªç ´â€ä½“éªŒæœŸé—´æ˜¾ç°ï¼Œè€Œä¸æ˜¯äºšçªç ´æ°´å¹³çš„æ—…ç¨‹ã€‚

    + **[æ°¸æ’ä¸»ä¹‰æ„ŸçŸ¥](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Perception of eternalism")**
    + **[è‡ªæˆ‘è®¾è®¡æ„ŸçŸ¥](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Perception of self-design")**
    + **[å®¿å‘½è®ºæ„ŸçŸ¥](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Perception of predeterminism")**
    + **[æ„ŸçŸ¥åˆ°æš´éœ²äºæ„è¯†çš„å†…éƒ¨æœºåˆ¶](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Perceived exposure to inner mechanics of consciousness")**
    + **[è”åˆä¸äº’è”](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Unity and interconnectedness")**

### ä½“éªŒæŠ¥å‘Š

æè¿°è¯¥åŒ–åˆç‰©æ•ˆåº”çš„è½¶äº‹æŠ¥å‘ŠåŒ…æ‹¬ï¼š

* [Experience: 40mg 5-MeO-DMT (oral) + 40mg MXE (oral) - Untitled](/æŠ¥å‘Š/psychounautwiki/Experience:_40mg_5-MeO-DMT_(oral)_%2B_40mg_MXE_(oral)_-_Untitled)
* [Experience:A combination of DOC, 5-MAPB, 5-MeO-DMT, ETH-LAD, Cannabis, Pentedrone](/æŠ¥å‘Š/psychounautwiki/Experience:A_combination_of_DOC,_5-MAPB,_5-MeO-DMT,_ETH-LAD,_Cannabis,_Pentedrone)

æ›´å¤šçš„ä½“éªŒæŠ¥å‘Šå¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°ï¼š

* [Erowid Experience Vaults: 5-MeO-DMT](https://www.erowid.org/experiences/subs/exp_5MeODMT.shtml)

ç»™è¯é€”å¾„
------------------------

### æ±½åŒ–

å½“ä»¥å…¶åˆæˆç²‰æœ«å½¢å¼æœç”¨æ—¶ï¼Œ5-MeO-DMT é€šå¸¸è¢«[æ±½åŒ–](/æ–‡æ¡£/ç»™è¯é€”å¾„.md "Routes of administration")ï¼ˆå¸å…¥è’¸æ±½ï¼‰ï¼Œä½†ä¹Ÿå¯ä»¥é¼»å¸ï¼ˆå°½ç®¡ä¸é¼“åŠ±è¿™æ ·åšï¼‰ï¼Œå¹¶ä¸”åœ¨ä½è‡³ 2 mg çš„å‰‚é‡ä¸‹å°±æœ‰æ´»æ€§ã€‚æœ‰äººè®¤ä¸ºå®ƒçš„æ•ˆåŠ›å¤§çº¦æ˜¯ DMT çš„ 4-5 å€ã€‚[\[6\]](#cite_note-6)

### å£æœ

ä¸ DMT ä¸€æ ·ï¼Œ5-MeO-DMT å·²è¢«è¯æ˜åœ¨ä¸ [å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚.md "MAOI") ä¸€èµ·æœç”¨æ—¶å…·æœ‰å£æœæ´»æ€§ï¼Œä½†æ ¹æ®å¤§é‡æŠ¥å‘Šï¼Œè¿™ç§ç»„åˆå¾€å¾€æå…¶ä»¤äººä¸å¿«ï¼Œé™¤äº†é«˜è¡€å‹ç—‡çŠ¶å’Œ[è¡€æ¸…ç´ ç»¼åˆå¾](/æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")çš„é£é™©å¤–ï¼Œè¿˜ä¼šäº§ç”Ÿå¼ºçƒˆçš„[èº¯ä½“ä¸é€‚æ„Ÿ](/è¯æ•ˆ/ä¸é€‚æ€§èº¯ä½“æ•ˆåº”.md "Body load")ï¼Œå› æ­¤å¼ºçƒˆå»ºè®®ä¸è¦è¿™æ ·åšã€‚[\[7\]](#cite_note-7) æ— è®ºæ˜¯åœ¨èº«ä½“è¿˜æ˜¯å¿ƒç†å±‚é¢ï¼Œå®ƒéƒ½è¢«è®¤ä¸ºæ¯” [DMT](./DMT.md "DMT") å®‰å…¨æ€§ä½å¾—å¤šå–µã€‚

å¤©ç„¶æ¥æº
---------------

### ç§‘ç½—æ‹‰å¤šæ²³èŸ¾èœ

[![](/æ–‡ä»¶/Bufo_alvarius1.jpg)](/æ–‡ä»¶/Bufo_alvarius1.jpg)

[![Status iucn3.1 LC.svg.png](/æ–‡ä»¶/Status_iucn3.1_LC.svg.png)](/æ–‡ä»¶/Status_iucn3.1_LC.svg.png)

ç§‘ç½—æ‹‰å¤šæ²³èŸ¾èœ (*Incilius alvarius*)ï¼Œä¹Ÿè¢«ç§°ä¸ºç´¢è¯ºæ‹‰æ²™æ¼ èŸ¾èœï¼Œæ˜¯ä¸€ç§å‘ç°äºå¢¨è¥¿å“¥åŒ—éƒ¨å’Œç¾å›½è¥¿å—éƒ¨çš„èŸ¾èœã€‚å®ƒçš„çš®è‚¤å’Œæ¯’æ¶²å«æœ‰ 5-MeO-DMT å’Œ [bufotenin](/è¯ç‰©/bufotenin.md "Bufotenin") (5-HO-DMT)ã€‚å¯ä»¥åœ¨ä¸ä¼¤å®³èŸ¾èœçš„æƒ…å†µä¸‹æ”¶é›†æ–°é²œæ¯’æ¶²ã€‚è¿™æ˜¯é€šè¿‡å°†é¢ˆéƒ¨åŒºåŸŸçš„è€³ä¸‹è…ºæŠšæ‘¸åˆ°å¹³æ¿ç»ç’ƒæ¿ä¸Šæ¥å®Œæˆçš„ã€‚æ¯’æ¶²å¹²ç‡¥åä¼šå‘ˆç°æ©¡èƒ¶æ°´æ³¥çš„è´¨åœ°ï¼Œç„¶åå¯ä»¥è¢«æŠ½å¸ã€‚è¯¥äº§å“å«æœ‰é«˜è¾¾ 15% çš„ 5-MeO-DMTï¼Œä»¥åŠ 5-MeO-NMT å’Œ [bufotenin](/è¯ç‰©/bufotenin.md "Bufotenin")ã€‚

#### å‰‚é‡

å‡è®¾æ¯’æ¶²ä¸­å¹³å‡è‡³å°‘æœ‰ 10% æ˜¯ 5-MeO-DMTï¼š

* **é˜ˆå€¼ï¼š** 10 - 20 mg
* **è½»å¾®ï¼š** 20 - 50 mg
* **ä¸­ç­‰ï¼š** 50 - 100 mg
* **å¼ºçƒˆï¼š** 100 - 200 mg

æ¯’æ€§å’Œå±å®³æ€§
---------------------------

- [![](/æ–‡ä»¶/Ambulance2.png)](/æ–‡ä»¶/Ambulance2.png) **è¿™éƒ¨åˆ†æ¯’æ€§å’Œå±å®³æ€§è¿˜åœ¨æ–½å·¥ä¸­å–µã€‚** å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´ç”šè‡³**å±é™©çš„é”™è¯¯**ä¿¡æ¯ï¼ä½ å¯ä»¥å¸®å¿™[æ‰©å±•æˆ–çº æ­£å®ƒã€‚](https://psychonautwiki.org/w/index.php?title=5-MeO-DMT&action=edit)
*æ³¨æ„ï¼šå¦‚æœä½¿ç”¨æ­¤ç‰©è´¨ï¼Œè¯·åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶å¹¶ä½¿ç”¨ **[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")**ã€‚*

æ›´å¤šä¿¡æ¯ï¼š[è´Ÿè´£ä»»çš„ç”¨è¯ Â§ è‡´å¹»å‰‚](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible use")

å¨±ä¹æ€§ 5-MeO-DMT çš„æ¯’æ€§å’Œé•¿æœŸå¥åº·å½±å“ä¼¼ä¹å°šæœªåœ¨ä»»ä½•ç§‘å­¦èƒŒæ™¯ä¸‹è¿›è¡Œç ”ç©¶ï¼Œç¡®åˆ‡çš„æ¯’æ€§å‰‚é‡æœªçŸ¥ã€‚è¿™æ˜¯å› ä¸º 5-MeO-DMT çš„äººç±»ä½¿ç”¨è®°å½•æœ‰é™ã€‚

è½¶äº‹è¯æ®è¡¨æ˜ï¼Œä»…ä»¥ä¸­ä½å‰‚é‡å•ç‹¬å°è¯•å¹¶éå¸¸èŠ‚åˆ¶åœ°ä½¿ç”¨å®ƒä¸å¤ªå¯èƒ½äº§ç”Ÿä»»ä½•è´Ÿé¢å¥åº·å½±å“ï¼ˆä½†ä¸èƒ½å®Œå…¨ä¿è¯ï¼‰ã€‚åœ¨æ¶ˆè´¹ä¹‹å‰ï¼Œåº”å§‹ç»ˆè¿›è¡Œ[ç‹¬ç«‹ç ”ç©¶](https://www.google.com/)ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆæ˜¯å®‰å…¨çš„ã€‚

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨æ­¤ç‰©è´¨æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible drug use")ã€‚

### ä¾èµ–æ€§å’Œæ»¥ç”¨æ½œåŠ›

ä¸å…¶ä»–[è¡€æ¸…ç´ èƒ½è¿·å¹»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Serotonergic psychedelics")ä¸€æ ·ï¼Œ5-MeO-DMT è¢«è®¤ä¸ºæ˜¯éæˆç˜¾æ€§çš„ï¼Œå…·æœ‰è¾ƒä½çš„æ»¥ç”¨æ½œåŠ›ã€‚æ–‡çŒ®ä¸­æ²¡æœ‰å…³äºæˆåŠŸè®­ç»ƒåŠ¨ç‰©è‡ªæˆ‘ç»™è¯ 5-MeO-DMT çš„æŠ¥å‘Šâ€”â€”è¿™æ˜¯ä¸€ç§é¢„æµ‹æ»¥ç”¨å¯èƒ½æ€§çš„åŠ¨ç‰©æ¨¡å‹â€”â€”è¡¨æ˜å®ƒä¸å…·å¤‡å¯åŠ¨æˆ–ç»´æŒä¾èµ–æ€§æ‰€å¿…éœ€çš„è¯ç†å­¦ç‰¹æ€§ã€‚

æœç”¨åå‡ ä¹ç«‹å³å°±ä¼šå¯¹ 5-MeO-DMT çš„æ•ˆåº”äº§ç”Ÿè€å—æ€§ã€‚ä¹‹åï¼Œå¤§çº¦éœ€è¦ 1 å°æ—¶è€å—æ€§ä¼šå‡åŠï¼Œ2 å°æ—¶åæ¢å¤åˆ°åŸºçº¿ï¼ˆåœ¨æ²¡æœ‰è¿›ä¸€æ­¥æ¶ˆè´¹çš„æƒ…å†µä¸‹ï¼‰ã€‚5-MeO-DMT ä¸å…¶ä»–[è¿·å¹»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Psychedelic")æ²¡æœ‰äº¤å‰è€å—æ€§ï¼Œè¿™æ„å‘³ç€åœ¨æ¶ˆè´¹ 5-MeO-DMT åï¼Œå…¶ä»–è¿·å¹»å‰‚çš„æ•ˆåº”ä¸ä¼šé™ä½ã€‚

### å±é™©çš„ç›¸äº’ä½œç”¨

***è­¦å‘Šï¼š*** *è®¸å¤šå•ç‹¬ä½¿ç”¨ç›¸å½“å®‰å…¨çš„ç²¾ç¥æ´»æ€§ç‰©è´¨ï¼Œå½“ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶ï¼Œå¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨æä¾›äº†ä¸€äº›å·²çŸ¥çš„å±é™©ç›¸äº’ä½œç”¨ï¼ˆå°½ç®¡ä¸ä¿è¯åŒ…æ‹¬æ‰€æœ‰ç›¸äº’ä½œç”¨ï¼‰ã€‚*

*åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com), [DuckDuckGo](https://www.duckduckgo.com), [PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆå¯ä»¥å®‰å…¨é£Ÿç”¨ã€‚åˆ—å‡ºçš„ä¸€äº›ç›¸äº’ä½œç”¨æ¥æºäº [TripSit](https://combo.tripsit.me)ã€‚*

* **[2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨.md)** (2C-T-X) - è¿™ä¸¤ç±»åŒ–åˆç‰©å•ç‹¬ä½¿ç”¨æ—¶éƒ½å¯èƒ½æ˜¯ä¸å¯é¢„æµ‹çš„ã€‚
* **[2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/2,5-äºŒç”²æ°§åŸºè‹¯ä¹™èƒºç±»ç‰©è´¨.md)** (2C-X) - 5-MeO è¿·å¹»å‰‚å¯èƒ½ä¼šä»¥ä¸å¯é¢„æµ‹çš„æ–¹å¼ç›¸äº’ä½œç”¨ï¼Œä»è€Œå¢å¼ºå…¶ä»–è¿·å¹»å‰‚çš„æ•ˆåº”ã€‚
* **[å¤§éº»](./å¤§éº».md)** - å¯èƒ½ä¼šå¢åŠ è´Ÿé¢å¿ƒç†æ•ˆåº”çš„é£é™©ï¼Œå¦‚[ç„¦è™‘](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Anxiety")ã€[åæ‰§](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md "Paranoia")å’Œ[ç²¾ç¥ç—…](/æ–‡æ¡£/å…´å¥‹å‰‚ç²¾ç¥ç—….md "Psychosis")ã€‚
* **DOx** - 5-MeO ç±»è‰²èƒºåœ¨ç›¸äº’ä½œç”¨ä¸­å¯èƒ½æ— æ³•é¢„æµ‹ï¼Œç‰¹åˆ«æ˜¯å¢åŠ äº†ä»¤äººä¸å¿«çš„èº«ä½“å‰¯ä½œç”¨çš„é£é™©ã€‚
* **[MDMA](./MDMA.md)** - ä¸€äº› 5-MeO è‰²èƒºæœ‰ç‚¹ä¸å¯é¢„æµ‹ï¼Œåº”å°å¿ƒä¸ MDMA æ··åˆä½¿ç”¨ã€‚
* **[éº¦æ–¯å¡æ—](./éº¦æ–¯å¡æ—.md)** - 5-MeO ç±»è‰²èƒºåœ¨ç›¸äº’ä½œç”¨ä¸­å¯èƒ½æ— æ³•é¢„æµ‹ã€‚
* **NBOMe** - 5-MeO ç±»è‰²èƒºåœ¨ç›¸äº’ä½œç”¨ä¸­å¯èƒ½æ— æ³•é¢„æµ‹ï¼Œè€Œ NBOMes ç”šè‡³å•ç‹¬ä½¿ç”¨ä¹Ÿä»¥ä¸å¯é¢„æµ‹è‘—ç§°ã€‚æœ€å¥½é¿å…è¿™ç§ç»„åˆã€‚
* **[è‹¯ä¸™èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¸™èƒºç±»ç‰©è´¨.md)** - å…´å¥‹å‰‚çš„ç„¦è™‘å’Œèšç„¦æ•ˆåº”å¢åŠ äº†ä»¤äººä¸å¿«çš„æ€ç»´å¾ªç¯çš„æœºä¼šã€‚ç”±äºè¿·å¹»å‰‚æœ¬èº«å…·æœ‰åˆºæ¿€ä½œç”¨ï¼Œè¿™ç§ç»„åˆé€šå¸¸æ˜¯ä¸å¿…è¦çš„ã€‚
* **[å¯å¡å› ](./å¯å¡å› .md)** - å…´å¥‹å‰‚çš„ç„¦è™‘å’Œèšç„¦æ•ˆåº”å¢åŠ äº†ä»¤äººä¸å¿«çš„æ€ç»´å¾ªç¯çš„æœºä¼šã€‚ç”±äºè¿·å¹»å‰‚æœ¬èº«å…·æœ‰åˆºæ¿€ä½œç”¨ï¼Œè¿™ç§ç»„åˆé€šå¸¸æ˜¯ä¸å¿…è¦çš„ã€‚
* **[å³ç¾æ²™èŠ¬](./å³ç¾æ²™èŠ¬.md)** (DXM) - å…³äºè¿™ç§ç»„åˆçš„ä¿¡æ¯å¾ˆå°‘ã€‚
* **[æ›²é©¬å¤š](./æ›²é©¬å¤š.md)** - å¢åŠ [è¡€æ¸…ç´ ç»¼åˆå¾](/æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")çš„é£é™©ã€‚
* **aMT** - å¢åŠ [è¡€æ¸…ç´ ç»¼åˆå¾](/æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")çš„é£é™©ã€‚
* **[å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚.md)** (MAOIs) - å¢åŠ [è¡€æ¸…ç´ ç»¼åˆå¾](/æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md "Serotonin syndrome")çš„é£é™©ã€‚
* **[PCP](./PCP.md)** - å…³äºè¿™ç§ç»„åˆçš„ä¿¡æ¯å¾ˆå°‘ã€‚å¯èƒ½ä¼šå¢åŠ ç²¾ç¥ç—…å’Œè¿‡åº¦åˆºæ¿€çš„é£é™©ã€‚

5-MeO-DMT è‡´æ­»çš„æƒ…å†µå¾ˆå°‘è§ã€‚ç„¶è€Œï¼Œä½œä¸ºä¸€ç§å¼ºå¤§çš„[å•èƒº](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Monoamine")[é‡æ‘„å–æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor") (MRI)ï¼Œ[\[5\]](#cite_note-pmid17223101-5) å½“æœç”¨è¿‡é‡æˆ–ä¸[å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚.md "MAOIs")ã€[å¯é€†æ€§å•èƒºæ°§åŒ–é…¶AæŠ‘åˆ¶å‰‚](/æ–‡æ¡£/å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚.md "RIMAs")ã€[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md "Stimulants")ä»¥åŠä»»ä½•ä½œä¸º[è¡€æ¸…ç´ ](/æ–‡æ¡£/è¡€æ¸…ç´ .md "Serotonin")å’Œ[å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md "Dopamine")ç­‰[ç¥ç»é€’è´¨](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Neurotransmitters")çš„[é‡Šæ”¾å‰‚](/æ–‡æ¡£/ç¥ç»é€’è´¨é‡Šæ”¾å‰‚.md "Releasing agent")æˆ–[é‡æ‘„å–æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md "Reuptake inhibitor")çš„ç‰©è´¨ä¸€èµ·æœç”¨æ—¶ï¼Œå¯èƒ½ä¼šå‘ç”Ÿä¼¤å®³ã€‚è¿™å·²å¯¼è‡´æœ‰æ®å¯æŸ¥çš„è‡´å‘½ä¸­æ¯’äº‹ä»¶[\[8\]](#cite_note-8)[\[9\]](#cite_note-9)ï¼Œè€Œè¿™äº›æœ¬æ¥æ˜¯å¯ä»¥é¢„é˜²çš„å–µã€‚

æ³•å¾‹åœ°ä½
------------

* **æ¾³å¤§åˆ©äºš**ï¼šä½œä¸º *N*,*N*-äºŒç”²åŸºè‰²èƒº (DMT) çš„ç»“æ„ç±»ä¼¼ç‰©ï¼Œæ ¹æ®æ¯’ç‰©æ ‡å‡†ï¼Œ5-MeO-DMT æ˜¯é™„è¡¨ 9 ç¦æ­¢ç‰©è´¨ã€‚[\[10\]](#cite_note-10)
* **å¥¥åœ°åˆ©**ï¼šä½œä¸º N,N-DMT çš„é†šï¼Œæ ¹æ® SMG (Suchtmittelgesetz Ã–sterreich)ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§å’Œé”€å”® 5-Meo-DMT æ˜¯éæ³•çš„ã€‚
* **å·´è¥¿**ï¼šæ‹¥æœ‰ã€ç”Ÿäº§å’Œé”€å”®æ˜¯éæ³•çš„ï¼Œå› ä¸ºå®ƒè¢«åˆ—å…¥ Portaria SVS/MS nÂº 344ã€‚[\[11\]](#cite_note-11)
* **ä¸­å›½**ï¼šæˆªè‡³ 2015 å¹´ 10 æœˆï¼Œ5-MeO-DMT åœ¨ä¸­å›½æ˜¯å—ç®¡åˆ¶ç‰©è´¨ã€‚[\[12\]](#cite_note-12)
* **æ·å…‹å…±å’Œå›½**ï¼š5-Meo-DMT åœ¨æ·å…‹æ˜¯åˆæ³•çš„ï¼›å› ä¸ºå®ƒæœªåˆ—å…¥ *Government Regulation n. 463/2013* (*NaÅ™Ã­zenÃ­ vlÃ¡dy Ä. 463/2013 Sb*)ã€‚[\[13\]](#cite_note-13)
* **ä¸¹éº¦**ï¼šæˆªè‡³ 2004 å¹´ 12 æœˆï¼Œ5-MeO-DMT åœ¨æ³•å¾‹ä¸Šä»…é™äºâ€œåŒ»ç–—æˆ–ç§‘å­¦ç›®çš„â€ã€‚
* **å¾·å›½**ï¼šæˆªè‡³ 2000 å¹´ 10 æœˆ 10 æœˆï¼Œ5-MeO-DMT æ ¹æ® Anlage I BtMGï¼ˆ*éº»é†‰å“æ³•ï¼Œé™„è¡¨ I*ï¼‰å—åˆ°ç®¡åˆ¶ã€‚[\[14\]](#cite_note-14)[\[15\]](#cite_note-15) æœªç»è®¸å¯åˆ¶é€ ã€æ‹¥æœ‰ã€è¿›å‡ºå£ã€è´­ä¹°ã€é”€å”®ã€è·å–æˆ–åˆ†å‘å‡å±è¿æ³•ã€‚[\[16\]](#cite_note-16)
* **å¸Œè…Š**ï¼š5-MeO-DMT äº 2003 å¹´ 2 æœˆ 18 æ—¥åœ¨å¸Œè…Šæˆä¸ºå—ç®¡åˆ¶ç‰©è´¨ [æ¬§ç›Ÿæ³•å¾‹æ•°æ®åº“]ã€‚
* **æ‹‰è„±ç»´äºš**ï¼š5-MeO-DMT æ˜¯é™„è¡¨ I è¯ç‰©ã€‚[\[17\]](#cite_note-17)
* **è·å…°**ï¼šç”±äº 5-MeO-DMT å¯è¢«è§†ä¸º bufotenin çš„é†šï¼Œæ ¹æ®è·å…°æ³•å¾‹ï¼Œå®ƒè¢«è§†ä¸ºæ¸…å• 1 é¸¦ç‰‡ç±»å—ç®¡åˆ¶ç‰©è´¨ã€‚[\[18\]](#cite_note-18) å°½ç®¡å¦‚æ­¤ï¼Œå®ƒå¯ä»¥é€šè¿‡è·å…°åœ¨çº¿ç ”ç©¶åŒ–å­¦å“é”€å”®å•†å…è´¹è·å¾—ã€‚
* **æ–°è¥¿å…°**ï¼š5-MeO-DMT åœ¨æ–°è¥¿å…°æ˜¯é™„è¡¨ Iï¼ˆA ç±»ï¼‰ã€‚
* **ç½—é©¬å°¼äºš**ï¼šè‡ª 2010 å¹´ 2 æœˆèµ·ï¼Œæ ¹æ®å—ç®¡åˆ¶ç‰©è´¨ç±»ä¼¼ç‰©æ³•æ¡ˆï¼Œåœ¨ç½—é©¬å°¼äºšç”Ÿäº§å’Œé”€å”® 5-MeO-DMT æ˜¯éæ³•çš„ã€‚[\[19\]](#cite_note-19)
* **ç‘å…¸**ï¼š5-MeO-DMT åœ¨ 2004 å¹´ 10 æœˆ 1 æ—¥çš„æ³•è§„ SFS 2004:696 ä¸­ï¼Œæ ¹æ®â€œLagen om fÃ¶rbud mot vissa hÃ¤lsofarliga varorâ€ï¼ˆè¯‘ä¸ºâ€œå…³äºç¦æ­¢æŸäº›å±å®³å¥åº·å•†å“çš„æ³•æ¡ˆâ€ï¼‰è¢«å½’ç±»ä¸ºå¥åº·å±å®³ï¼Œå› æ­¤é”€å”®æˆ–æ‹¥æœ‰æ˜¯éæ³•çš„ã€‚[\[20\]](#cite_note-20)
* **ç‘å£«**ï¼š5-MeO-DMT æ˜¯ Verzeichnis E ä¸­æ˜ç¡®å‘½åçš„å—ç®¡åˆ¶ç‰©è´¨ã€‚[\[21\]](#cite_note-21)
* **åœŸè€³å…¶**ï¼š5-MeO-DMT è¢«å½’ç±»ä¸ºæ¯’å“ï¼Œæ‹¥æœ‰ã€ç”Ÿäº§ã€ä¾›åº”æˆ–è¿›å£å‡å±è¿æ³•ã€‚[\[22\]](#cite_note-22)
* **è‹±å›½**ï¼š5-MeO-DMT åœ¨è‹±å›½æ˜¯ A ç±»è¯ç‰©ï¼Œå› ä¸ºå®ƒæ˜¯è¯ç‰© 5-HO-DMT çš„é†šï¼Œç”±äºè‰²èƒºåŒ…ç½—ä¸‡è±¡çš„æ¡æ¬¾ï¼Œ5-HO-DMT æ˜¯ A ç±»è¯ç‰©ã€‚[\[23\]](#cite_note-23)
* **ç¾å›½**ï¼š5-MeO-DMT äº 2011 å¹´ 1 æœˆ 19 æ—¥è¢«åˆ—å…¥é™„è¡¨ Iã€‚è¿™æ„å‘³ç€æœªç» DEA è®¸å¯åˆ¶é€ ã€è´­ä¹°ã€æ‹¥æœ‰æˆ–åˆ†å‘ï¼ˆé”€å”®ã€äº¤æ˜“æˆ–èµ é€ï¼‰å‡å±è¿æ³•ã€‚

å¦è§
--------

* [è´Ÿè´£ä»»çš„ç”¨è¯](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md "Responsible use")
* [è‡´å¹»åŸ](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Entheogen")
* [è¿·å¹»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md "Psychedelic")
* [è‰²èƒºç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‰²èƒºç±»ç‰©è´¨.md "Tryptamine")
* [DMT](./DMT.md "DMT")
* [Bufotenin](/è¯ç‰©/bufotenin.md "Bufotenin") (*5-HO-DMT*)

å¤–éƒ¨é“¾æ¥
--------------

* [5-MeO-DMT (Wikipedia)](https://en.wikipedia.org/wiki/5-MeO-DMT)
* [5-MeO-DMT (Erowid Vault)](https://erowid.org/chemicals/5meo_dmt/5meo_dmt.shtml)
* [5-MeO-DMT (TiHKAL / Isomer Design)](http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=38)
* [5-MeO-DMT (DrugBank)](https://go.drugbank.com/drugs/DB14010)

### è®¨è®º

* [The Big & Dandy 5-MeO-DMT Thread - First Launch (Bluelight)](http://www.bluelight.org/vb/threads/72085-The-Big-amp-Dandy-5-MeO-DMT-Thread-First-Launch)

æ–‡çŒ®
----------

* Ott, J. (2011). PharmepÃ©na-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine. Journal of Psychoactive Drugs, 33(4), 403-407. <https://doi.org/10.1080/02791072.2001.10399925>
* Shen, H.-W., Jiang, X.-L., Winter, J. C., & Yu, A.-M. (2010). Psychedelic 5-Methoxy-N,N-dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions. Current Drug Metabolism, 11(8), 659â€“666. <https://doi.org/10.2174/138920010794233495>
* Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. (2018). The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Journal of Psychopharmacology. <https://doi.org/10.1177/0269881118769063>

### ä¹¦ç±

* Oroc, J. (2009). Tryptamine Palace: 5-MeO-DMT and the Sonoran Desert Toad. Simon and Schuster.

å‚è€ƒèµ„æ–™
----------

1. [â†‘](#cite_ref-1) Barsuglia, J.; Davis, A. K.; Palmer, R.; Lancelotta, R.; Windham-Herman, A.-M.; Peterson, K.; Polanco, M.; Grant, Robert; Griffiths, R. R. (2018). ["Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study"](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6292276). *Frontiers in Psychology*. **9**: 2459. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.3389/fpsyg.2018.02459](//doi.org/10.3389%2Ffpsyg.2018.02459). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1664-1078](//www.worldcat.org/issn/1664-1078). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC") [701805890](//www.worldcat.org/oclc/701805890). [PMC](http://en.wikipedia.org/wiki/PubMed_Central "wikipedia:PubMed Central") [6292276](//www.ncbi.nlm.nih.gov/pmc/articles/PMC6292276) [Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/langen-gb-20px-Lock-green.svg.png "Freely accessible"). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [30574112](//www.ncbi.nlm.nih.gov/pubmed/30574112).
2. [â†‘](#cite_ref-TiHKAL_2-0) [Shulgin, Alexander](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md "Alexander Shulgin"); Shulgin, Ann (1997). ["#38. 5-MeO-DMT"](https://erowid.org/library/books_online/tihkal/tihkal38.shtml). *[TiHKAL: The Continuation](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md "TiHKAL")*. United States: Transform Press. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [0-9630096-9-9](http://en.wikipedia.org/wiki/Special:BookSources/0-9630096-9-9 "wikipedia:Special:BookSources/0-9630096-9-9"). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC") [38503252](//www.worldcat.org/oclc/38503252).
3. â†‘ [3.0](#cite_ref-Shen2010_3-0) [3.1](#cite_ref-Shen2010_3-1) Shen, H.-W.; Jiang, X.-L.; Winter, J. C.; Yu, A.-M. (2010). ["Psychedelic 5-Methoxy-N,N-dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions"](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3028383). *Current Drug Metabolism*. **11** (8): 659â€“666. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.2174/138920010794233495](//doi.org/10.2174%2F138920010794233495). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number") [1875-5453](//www.worldcat.org/issn/1875-5453). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1389-2002](//www.worldcat.org/issn/1389-2002). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC") [55201006](//www.worldcat.org/oclc/55201006). [PMC](http://en.wikipedia.org/wiki/PubMed_Central "wikipedia:PubMed Central") [3028383](//www.ncbi.nlm.nih.gov/pmc/articles/PMC3028383) [Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/langen-gb-20px-Lock-green.svg.png "Freely accessible"). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [20942780](//www.ncbi.nlm.nih.gov/pubmed/20942780).
4. [â†‘](#cite_ref-Krebs-ThomsonRuiz2006_4-0) Krebs-Thomson, K.; Ruiz, E. M.; Masten, V.; Buell, M.; Geyer, M. A. (2006). "The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats". *Psychopharmacology*. **189** (3): 319â€“329. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1007/s00213-006-0566-1](//doi.org/10.1007%2Fs00213-006-0566-1). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number") [1432-2072](//www.worldcat.org/issn/1432-2072). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0033-3158](//www.worldcat.org/issn/0033-3158). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC") [2409222](//www.worldcat.org/oclc/2409222). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [17013638](//www.ncbi.nlm.nih.gov/pubmed/17013638).
5. â†‘ [5.0](#cite_ref-pmid17223101_5-0) [5.1](#cite_ref-pmid17223101_5-1) Nagai, F.; Nonaka, R.; Satoh, K.; Kamimura, H. (2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". *European Journal of Pharmacology*. **559** (2â€“3): 132â€“137. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.ejphar.2006.11.075](//doi.org/10.1016%2Fj.ejphar.2006.11.075). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number") [1879-0712](//www.worldcat.org/issn/1879-0712). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0014-2999](//www.worldcat.org/issn/0014-2999). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC") [01568459](//www.worldcat.org/oclc/01568459). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [17223101](//www.ncbi.nlm.nih.gov/pubmed/17223101).
6. [â†‘](#cite_ref-6) Ott, Jonathan (2001). "PharmepÃ©na-Psychonautics: Human Intranasal, Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine". *Journal of Psychoactive Drugs*. **33** (4): 403â€“407. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1080/02791072.2001.10399925](//doi.org/10.1080%2F02791072.2001.10399925). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number") [2159-9777](//www.worldcat.org/issn/2159-9777). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0279-1072](//www.worldcat.org/issn/0279-1072). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [11824699](//www.ncbi.nlm.nih.gov/pubmed/11824699).
7. [â†‘](#cite_ref-7) ["5-MeO-DMT (5-Methoxydimethyltryptamine): Health"](https://erowid.org/chemicals/5meo_dmt/5meo_dmt_health.shtml). Erowid. September 2, 2010. Retrieved September 29, 2020.
8. [â†‘](#cite_ref-8) Brush, D. E.; Bird, S. B.; Boyer, E. W. (2004). "Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances". *Journal of Toxicology: Clinical Toxicology*. **42** (2): 191â€“195. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1081/clt-120030949](//doi.org/10.1081%2Fclt-120030949). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number") [1556-9519](//www.worldcat.org/issn/1556-9519). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1556-3650](//www.worldcat.org/issn/1556-3650). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [15214625](//www.ncbi.nlm.nih.gov/pubmed/15214625).
9. [â†‘](#cite_ref-9) Sklerov, J.; Levine, B.; Moore, K. A.; King, T.; Fowler, D. (2005). "A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation". *Journal of Analytical Toxicology*. **29** (8): 838â€“841. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1093/jat/29.8.838](//doi.org/10.1093%2Fjat%2F29.8.838). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN "wikipedia:International Standard Serial Number") [1945-2403](//www.worldcat.org/issn/1945-2403). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0146-4760](//www.worldcat.org/issn/0146-4760). [OCLC](http://en.wikipedia.org/wiki/OCLC "wikipedia:OCLC") [02942106](//www.worldcat.org/oclc/02942106). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier "wikipedia:PubMed Identifier") [16356341](//www.ncbi.nlm.nih.gov/pubmed/16356341).
10. [â†‘](#cite_ref-10) <https://www.legislation.gov.au/Details/F2016L01071/Html/Text#_Toc454279736>
11. [â†‘](#cite_ref-11) ["RESOLUÃ‡ÃƒO DA DIRETORIA COLEGIADA - RDC NÂ° 130, DE 2 DE DEZEMBRO DE 2016"](http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7) (in Portuguese). AgÃªncia Nacional de VigilÃ¢ncia SanitÃ¡ria (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]. December 5, 2016.
12. [â†‘](#cite_ref-12) ["å…³äºå°å‘ã€Šéè¯ç”¨ç±»éº»é†‰è¯å“å’Œç²¾ç¥è¯å“åˆ—ç®¡åŠæ³•ã€‹çš„é€šçŸ¥"](https://web.archive.org/web/20170906191704/http://www.sfda.gov.cn/WS01/CL0056/130753.html) (in Chinese). å›½å®¶é£Ÿå“è¯å“ç›‘ç£ç®¡ç†æ€»å±€ [China Food and Drug Administration (CFDA)]. September 27, 2015. Archived from [the original](http://www.sfda.gov.cn/WS01/CL0056/130753.html) on September 6, 2017. Retrieved August 19, 2020.
13. [â†‘](#cite_ref-13) <https://www.zakonyprolidi.cz/cs/2013-463>
14. [â†‘](#cite_ref-14) ["Gesetz Ã¼ber den Verkehr mit BetÃ¤ubungsmitteln: Anlage I"](https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html) (in German). Bundesamt fÃ¼r Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
15. [â†‘](#cite_ref-15) ["Vierzehnte Verordnung zur Ã„nderung betÃ¤ubungsmittelrechtlicher Vorschriften"](https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F*%5B%40attr_id%3D%27bgbl100s1414b.pdf%27%5D#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl100s1414b.pdf%27%5D__1576702069328). *Bundesgesetzblatt Jahrgang 2000 Teil I Nr. 44* (in German). Bundesanzeiger Verlag (published September 30, 2000). September 27, 2000. pp. 1414â€“1415. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0341-1095](//www.worldcat.org/issn/0341-1095). Retrieved December 18, 2019.
16. [â†‘](#cite_ref-16) ["Gesetz Ã¼ber den Verkehr mit BetÃ¤ubungsmitteln: Â§ 29"](https://www.gesetze-im-internet.de/btmg_1981/__29.html) (in German). Bundesamt fÃ¼r Justiz [Federal Office of Justice]. Retrieved December 10, 2019.
17. [â†‘](#cite_ref-17) ["Noteikumi par LatvijÄ kontrolÄ“jamajÄm narkotiskajÄm vielÄm, psihotropajÄm vielÄm un prekursoriem"](http://likumi.lv/doc.php?id=121086) (in Latvian). VSIA Latvijas VÄ“stnesis. November 10, 2005. Retrieved January 1, 2020.
18. [â†‘](#cite_ref-18) ["List 1 Controlled substances]"](https://web.archive.org/web/20210414060533/https://wetten.overheid.nl/BWBR0001941/2013-07-01) (in Dutch). Archived from [the original](https://wetten.overheid.nl/BWBR0001941/2013-07-01#LijstI) on April 14, 2021. Retrieved November 11, 2021.
19. [â†‘](#cite_ref-19) [*OUG 6 10/02/2010 - Portal Legislativ*](https://legislatie.just.ro/Public/DetaliiDocumentAfis/116209)
20. [â†‘](#cite_ref-20) ["Svensk fÃ¶rfattningssamling FÃ¶rordning om Ã¤ndring i fÃ¶rordningen (1999:58) om fÃ¶rbud mot vissa hÃ¤lsofarliga varor"](http://www.notisum.se/rnp/sls/sfs/20040696.pdf) (PDF) (in Swedish) (published September 7, 2004). August 19, 2004. SFS 2004:696.
21. [â†‘](#cite_ref-21) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
22. [â†‘](#cite_ref-22) Bakanlar Kurulu KararÄ± Karar SayÄ±sÄ± : 2013/4827 | <https://free-ankara.org/wp-content/uploads/2017/09/BKK_2013_4827_28688.pdf>
23. [â†‘](#cite_ref-23) ["Schedule 2: Part I: Class A Drugs"](http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I). *"Misuse of Drugs Act 1971"*. UK Government. Retrieved August 20, 2020.